ASC-101 and ASC-201 are exciting technology platforms developed to maximize the full potential of stem cells, including the potential to target large unmet medical needs and to treat chronic conditions such as cancer.
ASC-101 is a breakthrough human recombinant enzyme technology that increases the efficiency of engraftment in transplantation of cord blood derived stem cells.
Exciting in vitro and in vivo experimental results attest to the potential for ASC-101 to accelerate hematopoietic/immune system recovery, reducing the treatment-related mortality rate associated with infections during the patient’s immune-compromised period.
ASC-101 may also enable adult cancer patients requiring bone marrow transplants to be treated quickly with cord blood derived stem cells from a single cord blood unit, avoiding the long and often futile wait for matching bone marrow or peripheral blood derived stem cells.
ASC-201 is an enzyme inhibitor that enhances homing of stem cells to the bone marrow by increasing response to a natural homing signal.
Results from multiple laboratory studies attest to the beneficial effects of ASC-201 and demonstrate the potential of this technology to transform hematopoietic stem cell transplantation.
Enhanced homing to the bone marrow endothelium and increased engraftment in the bone marrow has been demonstrated using transplantation of mature bone marrow-derived stem cells as well as human cord blood derived stem cells.